CAM
SYRS

Cormorant Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Cormorant Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-29,630
Closed -$2.88M – 59
2017
Q4 		$2.88M Hold
29,630
– – 0.3% 47
2017
Q3 		$4.36M Hold
29,630
– – 0.77% 37
2017
Q2 		$4.77M Buy
+29,630
New +$4.66M 0.79% 36

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cormorant Asset Management's SYRS Position: Q1 2018 in Review

Cormorant Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2018, closing a stake of 29,630 shares — an estimated $2.88M sold.

Cormorant Asset Management first reported a position in SYRS in Q2 2017 and held it in 3 quarters. The position peaked at $4.77M in Q2 2017. 57 funds tracked by Wall St. Rank hold SYRS as of Q1 2018.

  • Cormorant Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Cormorant Asset Management sold 29,630 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $2.88M.
  • Cormorant Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • Cormorant Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4.77M in Q2 2017.
  • 57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Cormorant Asset Management's 13F filing for Q1 2018, filed 15 May 2018.